ETON
Eton Pharmaceuticals Inc
55.40$
+6.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 86.1% | 84.6% | 78.8% | 79.9% | 83.0% | 53.9% | 59.5% | 67.3% | 68.9% | 65.8% | 54.5% | 59.2% | |
| 70.0% | 67.4% | 54.1% | 55.6% | 56.5% | 19.6% | 20.7% | 25.0% | 35.5% | 28.2% | 20.1% | 23.2% | |
| 70.0% | 67.4% | 54.1% | 55.6% | 56.5% | 19.6% | 20.7% | 25.0% | 35.5% | 28.2% | 20.1% | 23.2% | |
| 11.1% | 10.7% | 13.8% | 15.3% | 15.6% | 7.0% | 19.5% | 14.2% | 12.5% | 12.8% | 13.7% | 21.5% | |
| 3.3% | 2.9% | 7.5% | 6.5% | 5.4% | 20.0% | 16.2% | 23.4% | 16.1% | 16.7% | 14.8% | 8.8% | |
| 13.4% | 14.9% | 20.7% | 19.2% | 16.3% | 45.8% | 40.3% | 32.3% | 30.5% | 33.5% | 44.8% | 39.4% | |
| 46.4% | 51.2% | 49.7% | 57.7% | 55.4% | 67.9% | 70.9% | 76.4% | 77.9% | 71.6% | 68.7% | 59.8% | |
| 33.0% | 51.2% | 49.7% | 57.2% | 55.1% | 26.2% | 30.2% | 38.0% | 42.3% | 41.8% | 45.2% | 39.0% | |
| 4.9% | 17.1% | 16.6% | 14.9% | 11.7% | 0.1% | 0.1% | 2.7% | 2.7% | 9.5% | 12.1% | 7.6% | |
| 5.4% | 5.8% | 7.3% | 6.7% | 7.5% | 5.5% | 5.8% | 11.9% | 13.6% | 11.9% | 13.8% | 12.4% | |
| 13.3% | – | – | – | – | 39.2% | 35.7% | 27.0% | 26.4% | 23.6% | 19.4% | 16.5% | |
| 53.6% | 48.8% | 50.3% | 42.3% | 44.6% | 32.1% | 29.1% | 23.6% | 22.1% | 28.4% | 31.3% | 40.2% | |
| -323.0% | -327.9% | -340.6% | -339.1% | -299.4% | -141.7% | -130.3% | -110.2% | -109.1% | -122.1% | -113.5% | -85.8% | |
| 81.6% | 81.1% | 83.7% | 81.0% | 74.1% | 34.3% | 32.0% | 26.4% | 25.7% | 29.2% | 32.3% | 28.3% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.